ChREBP及其靶基因PNPLA3在非酒精性脂肪性肝病发病中的作用  

Role of ChREBP and its target gene PNPLA3 in pathogenesis of nonalcoholic fatty liver disease

作　　者：季玲[1] 李昌平[1] 

机构地区：[1]四川省泸州医学院附属医院消化内科,四川省泸州市646000

出　　处：《世界华人消化杂志》2014年第2期179-183,共5页World Chinese Journal of Digestology

摘　　要：非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是肝细胞内大量甘油三酯聚集而引起的临床病理综合征,肝的组织学改变与酒精性肝病(alcoholic liver disease,ALD)相似,但无过量饮酒史.NAFLD包括非酒精性单纯性脂肪肝、非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)、NASH相关肝纤维化和肝硬化.目前其详细发病机制尚不清楚,但国内外已有较多关于ChREBP及其靶基因PNPLA3与NAFLD发病关系的研究,证实了ChREBP和PNPLA3与肝内脂肪含量及炎症相关.本文主要综述了ChREBP及其靶基因PNPLA3在NAFLD发病过程中的作用,为脂肪肝的发生和治疗提供更多的理论基础.Nonalcoholic fatty liver disease （NAFLD） is a clinical and pathological syndrome caused by excessive triglyceride accumulation in liver cells. Its hepatic histological changes are similar to those of alcoholic liver disease （ALD）, but the patients do not have a history of heavy alcohol drinking. NAFLD includes nonalcoholic simple fatty liver （NASFL）, nonalcoholic steatohepatitis （NASH） and nonalcoholic fatty hepatitis related to liver fibrosis and cirrhosis. At present, the detailed pathogenesis of NAFLD is unclear. Many studies have reported the relationship between ChREBP and its target gene PNPLA3 and NAFLD occurrence. ChREBP and PNPLA3 are associated with liver fat content and inflammation. This article reviews the role of ChREBP and its target gene PNPLA3 in the pathogenesis of NAFLD, in order to provide a theoretical basis for further research of the occurrence and treatment of NAFLD.

关 键 词：非酒精性肝病 ChREBP基因 PNPLA3基因 胰岛素抵抗 

分 类 号：R575.5[医药卫生—消化系统]